Hepatocyte growth factor (HGF), also known as scatter factor (SF), is produced by mesenchymal cells, including bone marrow (BM) stromal cells, and has mitogenic and motogenic effects on a variety of cell types. Recently, a role has been assigned to HGF/SF and its receptor, c-MET, in both normal and malignant hemopoiesis. We investigated the function of HGF/SF on hemopoietic mononuclear cells (MNC) from patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with circulating blasts. In contrast to results with normal MNC, HGF/SF alone stimulated the proliferation and colony formation of MNC from these patients. MNC from some (4/13) of the AML patients also produced HGF/SF (0.1-0.2 ng/ml/day), while we could not detect HGF/SF in cultures from normal MNC. Furthermore, it appeared that HGF/SF induced migration of leukemic cells in Boyden using KG1a cells as a model for leukemic blasts. The membranes dividing the two compartments of the Boyden chambers were coated with fibronectin. HGF/SF significantly promoted migration in 3/5 samples of MDS patients and in 5/7 samples of AML patients. Supernatant of human BM stromal cells, which is chemoattractive for normal human hemopoietic progenitor cells, also promoted migration of MNC from 4/5 MDS patients and 6/7 AML patients. Since HGF/SF is one of the growth factors produced by BM stromal cells, a neutralizing antibody directed against HGF/SF was added to the BM stroma supernatant, which reduced migration significantly in 2/3 MDS and in 3/6 AML responders to BM stroma supernatant. In conclusion, HGF/SF promotes proliferation and migration of hemopoietic cells from AML and MDS patients in vitro and may therefore contribute to the malignant potential of these cells.
Introduction
Hepatocyte growth factor (HGF), also known as scatter factor (SF), was first isolated from rat platelets and from plasma of patients with hepatic abnormalities. [1] [2] [3] [4] [5] HGF/SF is produced by a variety of mesenchymal cells as a single chain pro-HGF/SF, which is enzymatically, cleaved into biologically active HGF/SF consisting of an ␣-and a ␤-chain. [6] [7] [8] [9] [10] The receptor for HGF/SF is encoded by the MET proto-oncogene, c-MET, which is a cell surface tyrosine kinase receptor also consisting of an extracellular ␣-and a transmembrane ␤-chain. 11 The ␤-chain contains the tyrosine kinase domain, as well as sites for tyrosine autophosphorylation. 12, 13 HGF/SF regulates liver regeneration, and furthermore has mitogenic, morphogenic and motogenic effects on many different epithelial cells (eg mammary, kidney, intestinal and bronchial epithelial cells) as well as endothelial cells.
14- 20 However, among its pleiotropic effects, a role has also recently been assigned to HGF/SF and Correspondence: WR Gerritsen at his present address: Department of Medical Oncology, Academic Hospital Free University, Boelelaan 1117, 1007 MB Amsterdam, The Netherlands; Fax: 31204444355 Received 7 May 1997; accepted 20 February 1998 c-MET in hemopoiesis. 21, 22 HGF/SF was found to be synergistic with GM-CSF and IL-3 in proliferation of murine myeloid progenitor cell lines and murine hemopoietic progenitor cells (HPC) enriched from bone marrow (BM) or fetal liver. [23] [24] [25] Recently, three different groups, including ours, observed a synergistic proliferative effect of HGF/SF with other growth factors on human HPC, and detected c-MET expression in human CD34
+ HPC. [26] [27] [28] [29] In addition, HGF/SF promoted survival of human HPC and was detected in the supernatant of BM stromal cells. 27, 29 Apart from normal hemopoiesis, HGF/SF and c-MET seem to be involved in malignant hemopoiesis: In vitro HGF/SF production has been reported by leukemic and lymphoma cells and significant amounts of HGF/SF have been detected in blood and bone marrow plasma of leukemic patients. [30] [31] [32] Overexpression of c-MET, which may activate the proto-oncogene, has also been detected in some cases of human leukemia and lymphoma. 32, 33 Since these reports indicate that HGF/SF might play a role in leukemia, we investigated whether HGF/SF affected the function of leukemic cells. Using either peripheral blood (PB) or bone marrow (BM) samples from MDS (refractory anemia with excess blasts (RAEB) or RAEB in transformation (RAEBt) and AML patients, the effect of HGF/SF on proliferation of these leukemic cell samples was studied. HGF/SF alone promoted both proliferation and colony formation in these leukemic cell samples in a dose-dependent manner, while it did not exert this effect on normal PB or BM samples. Besides proliferation, the capacity of this growth factor to induce migration of leukemic cells was studied using Boyden chambers with fibronectin-coated membranes dividing the two compartments. HGF/SF promoted both adhesion to fibronectin and migration in Boyden chambers to a similar extent as supernatant from BM stromal cells, which is known to induce migration of hemopoietic progenitor cells.
Materials and methods

Cells
Normal bone marrow (BM) was aspirated from patients undergoing cardiac surgery after informed consent (approval by local ethical committee Academic Medical Center, Amsterdam, The Netherlands). Mononuclear cells (MNC) from normal bone marrow (BM MNC), from peripheral blood from healthy volunteers, or from bone marrow or peripheral blood of patients (see below) were isolated by density centrifugation (Lymphoprep, Nycomed Pharma, Oslo, Norway; density 1.077 g/ml; 20°C; 15 min at 2200 r.p.m.). Mononuclear cells were frozen in IMDM + 20% FCS + 20% DMSO in liquid nitrogen. Before use, cells were thawed and allowed to recover overnight in IMDM containing L-glutamine (Gibco/BRL, Gaithersburg, MD, USA), supplemented with 10% FCS (Bio Whittaker, Walkersville, MD, USA), penicillin (100 U/ml; Gibco/BRL) and streptomycin (100 g/ml; Gibco/BRL; P/S) with or without 10 ng/ml IL-1␤, 15 ng/ml HGF/SF, or 0.1 g/ml PMA (Fluka Chemie AG, Buchs, Switzerland) at 37°C. Then, supernatants were collected (to measure HGF/SF production by ELISA; see below) and cells were used for proliferation, adhesion and migration assays (see below). The KG1a cell line was obtained from the ATCC (Rockville, MD, USA) and maintained in culture medium (IMDM containing L-glutamine and P/S) with 5% FCS. Bone marrow stromal cells were cultured as follows: 6 × 10 6 BM-MNC were seeded in a 75 mm 2 flask in 6 ml 50% DMEM and 50% RPMI 1640 containing L-glutamine (Gibco/BRL) supplemented with 10% FCS (Bio Whittaker), P/S (100 U/ml penicillin; Gibco/BRL and 100 g/ml streptomycin: Bio Whittaker). After 1 day the medium was refreshed and only the adhering cells were kept in culture. Monolayers were grown and half of the medium was refreshed once a week. The supernatant of these BM stromal cells was used in migration experiments (see below) and the amount of HGF/SF present in the supernatant was tested by ELISA (see below).
Patients
MNC from 16 patients with a myelodysplastic syndrome (MDS) and from 16 patients with an acute myeloid leukemia (AML) were isolated and stored in liquid nitrogen before use. From the 16 MDS patients, 15 samples were obtained from peripheral blood and one sample from bone marrow. At the time of collection, 15 samples were from MDS patients with a diagnosis of RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation) and one sample from a patient with RA (refractory anemia). Six samples from AML patients were obtained from bone marrow and 10 from peripheral blood. The diagnosis of 10/16 AML patients were known for two patients with M1, five with M2, one with M3, one with M4, and two with M5, and was unknown for five patients.
Normal bone marrow (BM) was aspirated from patients undergoing cardiac surgery after informed consent (approval by local ethical committee Onze Lieve Vrouwe Gasthuis, and Academic Medical Center, Amsterdam, The Netherlands).
Cytokines
HGF/SF was a gift from Prof dr T Nakamura, Osaka, Japan.
Colony-formation assay
Mononuclear cells from MDS or AML patients or from normal bone marrow were used for the colony assays. 2 × 10 5 BM MNC were suspended in 1 ml of IMDM + L-glutamine (Gibco/BRL), supplemented with 10% FCS (Bio Whittaker), P/S, 7.3 × 10 −5 M ␣-monothioglycerol (Sigma, St Louis, MO, USA) and 0.36% agarose (SeaPlaque GTG; FMC, Rockland, ME, USA) and plated in triplicate in petri dishes (35 × 10 mm Falcon/Becton Dickinson, Plymouth, UK). Colonies were grown for 2-3 weeks, after which colony formation was scored using an inverted microscope. Colonies were scored when consisting of 50 cells or more. 
H-thymidine incorporation assay
Cell purification
CD34
+ cells were isolated using the VarioMACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany; gift from Amgen, Thousand Oaks, CA, USA). Briefly, mononuclear cells were incubated with a hapten-labeled antibody directed to CD34 (QBEND) in the presence of human IgG as a blocking reagent in PBE (PBS, 0.5% BSA, 5 mM EDTA) for 15 min at 4°C. Cells were washed in PBE and incubated with antihapten microbeads for another 15 min at 4°C. The labeled cells were washed and resuspended in PBE, passed through a 30 m nylon filter (Miltenyi Biotec) to remove cell aggregates. The cell suspension was applied to an RS + separation column, which was placed in the magnetic field of VarioMACS. The column was washed four times to remove CD34 − cells and the CD34
+ cells were eluted with 1 ml PBE after removing the column from the VarioMACS. The cells were further purified using a new RS + separation column after which at least 95% of the cells expressed CD34 (as measured by FACS).
HGF/SF ELISA
An HGF/SF-ELISA kit (Institute of Immunology, Tokyo, Japan) determined the level of HGF/SF. HGF/SF detection is based upon a sandwich method using a solid phase coated antihuman HGF/SF mouse monoclonal antibody and a peroxidase-labeled anti-human HGF/SF mouse monoclonal antibody. Amounts from 0.1 ng/ml were reliably detected according to the linearity of the standard curve. Supernatants were diluted 1:2 with sample dilution buffer. No HGF/SF was detected in culture media containing 5% or 10% FCS.
Adhesion assay
Adhesion assays were performed as described by Sonnenberg et al. 34 Ninety-six-well plates (U-bottom; Greiner, Kernsmunster, Austria) were coated overnight at 4°C with 20 g/ml of bovine fibronectin (FN; Sigma). Plates were washed three times with PBS and blocked with 1% BSA in PBS for at least 1 h at room temperature. Mononuclear cells were labeled with Na 2 51 CrO 4 (Amersham, Essex, UK) for 30 min, washed three times and resuspended in IMDM containing L-glutamine and 0.35% BSA at a concentration of 1 × 10 6 cells/ml. The cells were preincubated with HGF/SF (5-50 ng/ml) or PMA (0.1 g/ml; Fluka Chemie, Switzerland) for 10 min at 37°C. Thereafter, 100 l of the cell suspension (including HGF/SF or PMA) was plated in the FN-coated wells. Cells were allowed to adhere to the extracellular matrix molecule for 30 min at 37°C after which the wells were gently washed in IMDM + L-glutamine + 0.35% BSA at least five times until no more floating cells were seen with an inverted light microscope. Finally, the adherent cells were lysed with 0.2% SDS and counted in a gamma-counter (Packard). The percentage of cells that had adhered was calculated by dividing the measured radioactivity by that of the cells added (set at 100%). All incubations were performed in triplicate.
Migration assay
Boyden chambers (24-well plates; Becton Dickinson, Mountain View, CA, USA) were used to assess migration as described previously by Albini et al. 35 Upper and lower chambers of the Boyden chambers were separated by human fibronectin-coated membrane with 3 m pores (Becton Dickinson). Cells (3 × 10 5 ) were seeded in the upper chambers in culture medium (IMDM containing L-glutamine, supplemented with containing 5% FCS and P/S) and HGF/SF (5-50 ng/ml), supernatant of BM stromal cells (1:2 diluted with culture medium without FCS to obtain a final concentration of 5% FCS), monoclonal anti-HGF/SF (10 g/ml; neutralizing antibody; R&D, Oxon, UK), or monoclonal anti-IL-10 (10 g/ml;. neutralizing antibody; R&D, Oxon, UK) were added to the lower chambers in the same culture medium as present in the upper wells. The chambers were incubated overnight at 37°C. The cells that had migrated from the upper to the lower chamber were counted using an inverted light microscope. Three different fields or all cells (depending on the cell number) of the lower chamber were counted with a 20 × ocular.
Statistical analysis
All results were expressed as the mean ± standard deviation (s.d.). Significance levels were determined betweeen different groups in the proliferation, adhesion and migration assays using the two-tailed Student's t-test.
Results
Proliferation of MDS and AML cells by HGF/SF
Normal hemopoietic cells, including CD34
+ purified cells, do not proliferate or form colonies in the presence of HGF/SF alone. 23, [26] [27] [28] [29] Peripheral blood or bone marrow samples were obtained from MDS patients with circulating blasts or AML patients. MNC from 10/16 MDS patients responded to HGF/SF as measured by an increase in thymidine incorporation (mean ± s.d.: 4.1 ± 3.2, n = 10; Table 1a ). Within the MDS population 6/7 patients formed more colonies (mean ± s.d.: 2.0 ± 1.1) in the presence of HGF/SF (Table 1a) . Proliferation of AML samples increased 2.3 ± 2.9 (mean ± s.d., n = 8) in 8/16 patients in the thymidine assay and 1.9 ± 0.7 (mean ± s.d., n = 7) more colonies were found in 7/8 AML patients (Table 1b) .
A clear dose-effect of HGF/SF was seen in most of the patients (Figure 1 ). Both colony formation and thymidine incorporation was studied in 14 AML/MDS patients and similar results were seen in both assays (Table 1a and b). The FAB classification of 11 AML patients (M1: n = 2, M2: n = 5, M3: n = 1, M4: n = 1, M5: n = 2) was available, but the number of patients per subgroup was too small to draw any conclusions.
HGF/SF was produced by KG1a cells (33.5 ng/ml/10 6 cells/24 h). In 4/10 AML samples tested, significant HGF/SF levels (0.10 (patient 2, 
HGF/SF effect on migration of leukemic cells
KG1a is a CD34
+ leukemic cell line, which migrates spontaneously (2-5%) in fibronectin (FN)-coated Boyden chambers. BM stromal cell supernatant contains chemoattractants, such as SDF-1, and promotes migration of KG1a cells (256 ± 118%) ( Table 2 ). Since BM stromal cells also produce HGF/SF (2 ng/2 × 10 5 cells in 3 days of culture), the effect of HGF/SF on migration of leukemic cells was investigated. HGF/SF (25 ng/ml) in the lower compartment significantly promoted migration of KG1a cells (166 ± 44%) in comparison to medium control (100 ± 10%). Checkerboard analysis revealed that KG1a cells migrated only when HGF/SF was present in the lower compartment (Table 2) . A neutralizing antibody against HGF/SF inhibited migration of KG1a cells induced by BM stroma supernatant or HGF-SF. Spontaneous migration was not affected by the neutralizing antibody. An irrelevant antibody (monoclonal antibody against IL-10) did not affect migration.
KG1a cells only migrated when Boyden chambers contained membranes coated with fibronectin (FN). Compared to medium control, 160 ± 40% (n = 3) of the cells migrated through the FN-coated membrane in the presence of HGF/SF while only 10 ± 6% (n = 3) reached the lower chamber using uncoated membranes. For the rest of the experiments FNcoated membranes were applied.
These results with KG1a cells suggest that HGF/SF promotes migration of leukemic cells. Further migration experiments with normal CD34 + BM cells were carried out to investigate whether this feature is specific for leukemic cells or for normal and malignant CD34 + cells. HGS/SF also induced migration of normal CD34 + BM cells similarly to KG1a cells (Table 3) .
Effect of HGF/SF on samples from MDS and leukemia patients
The results with the leukemic cell line KG1a indicated that HGF/SF is a cytokine which is produced by BM stromal cells and promotes migration of KG1a cells through FN-coated membranes in Boyden chambers. To test whether HGF/SF affects proliferation and migration of leukemic cells obtained from patients, we collected cells from MDS patients with circulating leukemic blasts and cells from AML patients. Pilot experiments (n = 4) with MNC from MDS and AML patients confirmed our previous observations with normal hemopoietic progenitor cells and Burkitt cell lines 22, 27 which showed that HGF/SF promotes adhesion of hemopoietic cells to fibronectin. HGF/SF promoted adhesion of MNC from 1/2 MDS (from 47% with medium to 56% with 50 ng/ml HGF-SF; Figure 2a ) and 2/2 AML patients (from 33% to 69% with HGF/SF (Figure 2b ) and in the other patient from 58% to 67% to immobilized fibronectin. The effect of HGF/SF was quantitatively similar to the positive control PMA. Since adhesion to fibronectin could be the first step in migration, we tested whether HGF/SF induced migration using Boyden chambers of which the membrane dividing the two compartments was coated with fibronectin. Cells were placed in the upper chamber and medium with or without HGF/SF was placed in the lower chamber. Cells that crossed the filters with pores of 3 were counted after 16 h. As the pores are smaller than the cells, migration from the upper to the lower chamber is an active process. Differences in migration rate were assessed by counting cells on the bottom of the lower chamber in three different fields with an inverted microscope. Spontaneous migration of the MNC with control medium was between approximately 0.01 and 1% of the number of cells placed in the upper chamber.
MNC (3 × 10 5 ) from five MDS patients were mounted in the upper chamber and HGF/SF significantly promoted migration in 3/5 MDS patients by a 2.6 ± 0.8-fold (mean ± s.d.; Table 4 ) compared to control medium. BM stroma supernatant induced migration significantly in the same three patients and in an additional patient (total 4/5 patients) by a 3.2 ± 1.4-fold (mean ± s.d.; Table 4 ). Migration induced by supernatant of BM stromal cells was partly inhibited by addition of anti-HGF/SF in two patients (patients 3 and 4; Table 4 ) and significantly decreased in another two cases (patients 3 and 4; Table 4 ). HGF/SF enhanced migration of 5/7 AML samples significantly with a 1.8 ± 0.2 increment (Table 4 ). BM stroma supernatant gave similar results in 6/7 cases with a mean increase of migrated cells of 2 ± 0.6. Again, addition of anti-HGF/SF had an inhibitory effect on the BM stromal cell supernatant induced migration, which was significant in 3/6 responders ( Table 4) .
In contrast to patient material migration of normal PBMC was not detected in five cses. These data with patient samples indicate that a small proportion of the cells migrated in response to HGF/SF. Because of the low number of migrating cells, phenotypic analysis of the migrating cells could only be 3 × 10 5 KG1a were mounted in the upper wells of Boyden chambers. After 24 h all cells that had migrated to the lower chamber were counted with an inverted microscope. Spontaneous migration (with medium) was set at 100%. Number of experiments performed is indicated (n) and the s.d. between the experiments is shown. HGF/SF (25 ng/ml), supernatant of BM stromal cells (BM stroma sup), and neutralizing anti-HGF/SF (10 g/ml) were put in the lower chambers unless otherwise indicated. In all upper and lower wells culture medium with 5% FCS was present. a Number of migrated cells is significantly increased compared to medium alone (P Ͻ 0.05). b Number of migrated cells is significantly decreased compared to spontaneous migration (P Ͻ 0.05).
Figure 1
Number of colonies grown after 2 weeks of 2 × 10 5 BM MNC from a representative MDS patient in agarose in the presence of different concentrations of HGF/SF. Values are mean number of colonies ± s.d. from triplicates. *,**: indicates that the number of colonies is significantly increased compared to no addition of HGF/SF (*: P Ͻ 0.05; **: P Ͻ 0.01).
performed in two samples. In both cases the percentage of CD33 + cells and CD34 + cells in the cell population, which reached the bottom of the Boyden chamber, were comparable to the proportion of immature cells in the starting material, suggesting that HGF/SF not only induced migration of leukemic blasts but also of other cells.
Discussion
This report shows that HGF/SF has both mitogenic and motogenic effects on leukemic cells. HGF/SF is produced by bone marrow stromal cells and exerts a synergistic effect on normal HPC from peripheral blood or bone marrow, which are c- Table 3 HGF/SF-induced migration of normal human BM CD34 MET positive. [22] [23] [24] [25] [26] [27] [28] [29] c-MET encodes the receptor for the ligand HGF/SF, which belongs to the tyrosine kinase receptor family, and is expressed on CD34 + cells. The HGF/SF receptor is expressed on leukemic cell lines and leukemic blasts 32, 33 and in MDS samples. 36 These reports prompted us to investigage further the functional role of HGF/SF on leukemic cells. While normal PBMC or bone marrow MNC do not proliferate in the presence of HGF/SF, 27 HGF/SF stimulated the proliferation or colony formation of peripheral blood or bone marrow samples, which contained leukemic cells. This observation suggests that HGF/SF had a direct effect on the leukemic cells in both the thymidine incorporation assay as well as the colony formation in soft agar. The effects of HGF/SF on MDS and AML cells, are reminiscent of those obtained with another tyrosine kinase receptor FLT3 (also known as FLK2 and STK-1) and its ligand FL. FLT3 is expressed in human acute leukemias of the myeloid and lymphoid lineages. [37] [38] [39] [40] Like HGF/SF, FL also stimulates the growth of myeloid leukemic cells alone and is a synergistic proliferative factor with other growth factors. 41 Furthermore, the HGF/SF receptor is only expressed on a small minority of peripheral blood cells, 22, 27 while it is expressed on leukemic cells, 22, 32, 33, 36 supporting the hypoth- . Values are means of triplicate wells ± s.d. *,**: indicates that adhesion is significantly different from adhesion obtained without stimuli (*P Ͻ 0.05; **: P Ͻ 0.01). HGF/SF significantly (P Ͻ 0.05) increased adhesion of MNC from the second AML patient from 58 ± 3% to 71 ± 3%, which was at the same level as observed with PMA (69 ± 2%). esis that HGF/SF has a direct effect on leukemic cells. However, since mixtures of cells were used for this set of experiments we cannot rule out that the observed effects in the proliferation assay or colony assay is the result of a synergistic effect of HGF/SF with other cytokines produced by leukemic cells or other cell populations within the patient samples.
Hemopoietic cells from AML patients produce small amounts of HGF/SF during 24 h of culture, while normal BM MNC did not. This is in line with the observations that HGF/SF has been found in blood and bone marrow plasma of leukemia patients 30, 32 as well as in supernatants of human leukemia cell lines 31, 42, 43 and myeloma cells. 44 Transfection of the HGF/SF gene and/or c-MET gene in several epithelial cell lines and NIH3T3 cells [45] [46] [47] [48] [49] [50] [51] [52] has revealed that these genes influence the invasiveness of these cells. Furthermore, studies for the expression pattern in normal, premalignant and malignant lesions has demonstrated overexpression of the c-MET gene in different tumors. [53] [54] [55] [56] HGF/SF is produced by several epithelial tumors. 57, 58 Production of HGF/SF by breast cancer cells, measured either in serum of patients or in tumor extracts, is an indicator of aggressive behavior of the tumor. 59, 60 These reports about epithelial tumors indicate that HGF/SF and its receptor might play a role in determining the aggressiveness of an epithelial tumor. Our results and the reported production of HGF/SF by leukemic cell lines may warrant further clinical studies as to whether HGF/SF production in leukemic patients might be an indicator for the clinical behavior of leukemia, especially since our results indicate that HGF/SF affects both proliferation and migration of leukemic cells.
HGF/SF not only affected directly or indirectly proliferation of leukemic cells, but also had an effect on migration of leukemic cells. KG1a leukemic cells migrated over fibronectincoated membranes in Boyden chambers. The pores in the Boyden chambers were much smaller (3 ) than the size of the cells (10) (11) (12) ) indicating that migration would require an active change of shape and active movement of the cells.
HGF/SF only induced migration of the KG1a cells when the filters were coated with fibronectin suggesting that adhesion to fibronectin is the first step in the migration process. Previously, we demonstrated that HGF/SF promotes adhesion of CD34 + cells and Burkitt lymphoma cells to fibronectin in a dose-dependent manner. 22, 27 This adhesion to fibronectin was mediated by the integrins ␣ 4 ␤ 1 and ␣ 5 ␤ 1 . Additional experiments with normal CD34 + cells indicate that the effect of HGF/SF on KG1a cells is not exclusive for leukemic cells, but merely an effect of HGF/SF on migration of early myeloid progenitor cells. The data with KG1a cells and CD34
+ cells indicate that HGF/SF affects to the same extent the number of migrating leukemic cells, which is only a very small proportion of the cells. The small proportion of cells is dependent on the pore size, since additional experiments have shown that more cells migrate when bigger pore sizes are applied (Voermans, unpublished observations).
The addition of HGF/SF in the Boyden chambers promoted migration from MNC from MDS and AML patients. Three of five MDS patients and 5/7 AML patients showed a marked migration in response to HGF/SF. Supernatant of BM stromal cells, which contains a strong chemoattractant (SDF-1) for hemopoietic progenitor cells, was superior to HGF/SF in inducing migration 61, 62 (Table 4 ). The chemoattractive property of BM stroma supernatant was partially reversed by the addition of a neutralizing monoclonal antibody directed to HGF/SF, suggesting that HGF/SF, which is present in supernatant of BM stromal cells (approximately 1-2 ng/ml; 27 ), is at least partly responsible for the migration promoting effect.
Since 5-12% of the KG1a cells migrated to the lower chamber, it was not surprising that only a very small proportion of the AML/MDS cells passed through the membranes. The phenotypic analysis of the migrating cells may indicate that HGF/SF does not affect migration of a specific subpopulation of cells, but rather of a mix of cells including immature myeloid cells.
In conclusion, HGF/SF promotes proliferation, adhesion to fibronectin, and migration in Boyden chambers of hemopoietic cells from MDS and AML patients. Therefore, the HGF/SF-c-MET interaction may increase the malignant potential of MDS and AML cells not only by increasing proliferation, but also by promoting migration. Additional studies are warranted with purified leukemic cell populations to support these observations that HGF/SF has a direct effect on leukemic cells.
